Sunshine Biopharma (SBFM) Total Liabilities (2010 - 2026)

Sunshine Biopharma's Total Liabilities history runs 16 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• Quarterly Total Liabilities fell 1.09% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 1.09% YoY) and the FY2025 annual result came in at $7.0 million, changed 0.27% from the prior year.
• Total Liabilities was $6.4 million for Q1 2026 at Sunshine Biopharma, down from $7.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $7.6 million in Q4 2022 and bottomed at $95234.0 in Q1 2022.
• A 5-year average of $5.4 million and a median of $6.3 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities sank 96.76% — and 2023, when it surged 7840.3%.
• Sunshine Biopharma's Total Liabilities stood at $7.6 million in 2022, then dropped by 19.39% to $6.1 million in 2023, then climbed by 14.99% to $7.1 million in 2024, then slipped by 0.27% to $7.0 million in 2025, then slipped by 8.9% to $6.4 million in 2026.
• Business Quant data shows SBFM's Total Liabilities at $6.4 million in Q1 2026, $7.0 million in Q4 2025, and $7.3 million in Q3 2025.